XXXX full our results. to you you, for Thank today and Nichol, joining all QX us year review and thank
has we to we the strategic of back A year, successful want an about we investors and focused into enthusiasm name Zevra Before Today, and here new today we’re past it share walk over how evolution where for through a happened overview months. Therapeutics, is and a our our get XX got are provide our step to company. I a my important rare with talk take future. lot and the the focus, highlights and at disease of nimble
approval. successful patients drug a Our has track in as in tackling need well development team and success in regulatory as challenges of championing and overcoming record
chart candidates. and our We of expertise drug success for a to are leveraging insights for promising unique development years product forging to new and course pathways
through move As to discovered leverage internally with we cycle exclusivity this forward, extend our Zevra their way, we our disease and life will pipeline target legacy rare assets opportunities In and platform diseases product create for management. transformational value shareholders. bring rare patients therapies continue to families our and we to hope and
coming we rare multiple success, year. milestones expected robust product disease are positioned we a the well candidates have with promising over pipeline Importantly, value-creating for of
strong and a disease. rare with trajectory accomplished it team product successful have of we We Supporting Board experience world-class all, that strategic in with approvals an leadership have numerous our of sheet. align the Directors a equally balance
in of Board thoughtfully company's management We've over team strategy collaboration So the our with Directors led how and by supported shareholders. hard evolve our here? past did we by get to years, the our worked X
in on what put the After we evaluate financial the the licensing our AZSTARYS management where and and a company actions to and we approval, to and getting AZSTARYS, team market. commercialization to the Board learned firmer footing, of pause were
have our shareholders strong our in capabilities time a that we a value path frame in areas. development scale create We determine and to at success best and was and to the that scientific, objective concluded Our regulatory forward deserve.
generic and products pipeline heavily of on compete eventually focusing would delivering investment in that our a return of those However, our to on to candidates a as out-licensing product significant likely a shareholders. objective fail will markets meet exclusively commercial strategy
to thoughtfully that -- benefit we no the work commercial with Zevra value on work treatment of products a an our NDA-stage delivering destiny together States. cash the capabilities therapeutics limited shareholders. commercializing course product with approvals strengths We organization's set series strategy, create strategic the on transformative of company, thoughtfully, new us the options. focusing goal a control the candidate then our our rare existing new acquisition patients upon disease We then with took United arimoclomol indications the in highlighted align intend to will for the enable retain This strengths perfectly and a of hard-earned capitalizes refined commercial build our with our while or actions bringing position that of by of and to allow to on to for needed much value to we which direction focus
drug It mass to rare for experience, rare over note is in development recognize in disorders KPXXXX with From sleep We already offers with new idiopathic advantages entirely were us. significant technology an we market rare focus hypersomnia. disease in applied large for is working rare important disease development that that that indications. not our several disease prodrug
to of that quality management biggest privilege disease patients, we and success. ensures and of life understand partnering capable approaches deeply relevant of our answering families and therapeutic the our advocacy groups their concerns. This First needs and have are and commercial their products are foremost, ensure with
smaller voucher of shorter and therapeutics Drug Act, Rare the and Orphan protection for for products extended Through market and such as indications patent much priority disease development. research exclusivity. than from the and in for incentives, longer company receive the benefits resulting studies review review diseases larger X-month cost lower drug window lines development rare resulting time often a are pursuing involve
to patient own in-house population Disease treated primarily commercialization small significant products a not patents experience Rare can products we our do team. clinicians, with competition expire. by with once also commercial specialist bring those generic Moreover,
we to focus and acquisition, disease Niemann-Pick led disease we our this platform creates creation acquisition disease on strategic saw to rare rare for high Taking together, drug This value acquired a arimoclomol. that for ideal product candidate and of C. Type potential Through shareholders. decision maximizing an that development for our patients exclusively
also an onboarded rare amazing European We significant community team connections deep NPC with patient expertise. the drug and development to disease
as on no focusing began KemPharm we name we company. we our a and is As rare reflected recognize that diseases, longer are who branding
rare a brand we underwent commitment deserve. patients our The we messaging and branding our process process name, Therapeutics disease the of Zevra reflect that redefine story. So new outcome is to our to and to
which perfectly is zebra, recognized symbol people expressions Greek for empowering Zevra we Zevra [sells] is about a the diseases. called our for team of Interestingly, also internationally disease with rare rare capture are as these word is [indiscernible], community. The group
rare We are dazzling confident the future envision for that Zevra we a is with and that communities we will a serve. patients, resonate that disease name
Zevra secure at pipeline and work approval is any we priorities pipeline regulatory for towards build internal history key better assets, top-tier our today positioned efforts. external than our enhance to and its capabilities, our through point in as commercial
milestones candidates two strong have product year. We with expected multiple value-creating this very
development new opportunities both platform activities product continue through disease. business explore We focused and prodrug on rare to our
a growing we stream financial that a company, We position. in revenue a have strong rare as already beast stage our which development are already bolsters
and and portfolio diverse in our strong deliver financial beyond. of our programs and ability confident foundation XXXX value team the am in clinical I multiple and to in
company. Importantly, candidate that a was rare to a we of organization our NPC. evolution a us of in has that engaged and product Board help in the completion and our supportive into XXXX safety have company can deeply Directors our advance of strategic fully and year involved of our pivotal with X-year for acquisition arimoclomol disease been a the study evolution and
collaborative the program in around been dialogue preparing resubmission. with us ongoing Our NDA highly the has productive for FDA
a exclusivity sleep headway data in I after including the program designation We've a for regulatory in candidate from trial KPXXXX primary KPXXXX Orphan IH our approval. also of including rare incentives product made over in earlier, last idiopathic disorders and hypersomnia. our year, SDX, this tremendous positive of drug the cardiovascular Phase component initiation trial market extended provides II advantages highlighted in for
nearly strong the earning following fee ADLARITY. continue financial to Corium of from million of bolster our approval We position, $X FDA onetime a
revenue Cash, equivalents cash and as year net full December $XXX.X million. for of were XXXX, was million. the XX, $XX.X investments Our
enviable Our available XXXX, for capital any markets. is an company expected position biotech in into today's capital to extend cash our runway
by Relations In we of team XXXX, began Communications. our to build appointing further our VP Nichol as and Corporate efforts Ochsner, Investor
to an director, Board independent Posner addition great team. another In addition, the as appointed the Christopher
at arimoclomol arimoclomol program will of II/III which as interim As the a of study see the of from the analysis fronts. application new out demonstrate early the you the a fourth several expected of data, the from the tremendous recent presentation quarter those. These XXXX this Phase data of of drug safety quarter on resubmission benefit momentum the third a in we've XXXX I point WORLDSymposium. our as few year. clinical slide, the X-year of of of and this XXXX in a Notably, development want to beginning had the cornerstone was be can
This improve outcomes suggests our you reduce you understanding data progression lysosomal that can of if NPC. that for the can the underscores arimoclomol improve Notably, may function, patients.
we engage rebrand our disease as alignment with disease joined, company We identity Therapeutics also strategic a rare underwent NORD with rare further Corporate our to the Zevra community Counsel. in to and the
take experience also members of group we us several of executive made with and can appointments of we only accomplished with an are Zevra our success. and have our direction that that additional legacy but confident commercialization we leadership year, skills our are talent our lead of Directors, Shown into team are R&D transformation can aligned the is not the new of and in I'm and key strengthening the blend team Board leadership, rare Board beginning the company. disease decades and The to Directors, future a a with team into and a future. Since of here team changes into
in Arimoclomol like orally has X Union pediatric varying I'd studied approved be designation, breakthrough would voucher. the for C. program Arimoclomol candidate turn designation therapy of Phase Track NPC. NPC trials. European and and been eligible If review to This and Phase in received Disease attention FDA in United U.S., the for to also for Now ease and Niemann-Pick use pivotal priority a Type our in II Fast to orphan II/III for I, formulated arimoclomol product has circumstances. from and pediatric Phase XX is administered the States the disease our is X patient designation designation drug receive arimoclomol rare
are new FDA to drug for year third as the early this on track arimoclomol. application as of submit the We quarter to the
our for the to have the to program product we it approved, most the arimoclomol the full market opportunity aspects One value is ourselves of near-term be the attractive shareholders. of should it that commercialize retain
team centers new a commercial advocacy believe arimoclomol, that through the We population treating our entry specialists lower NPC patient cost support small relationships a the team access the small in our market with population. We established and established and and entry. early community the and believe of patient of nimble medical and fully already could of is commercial benefit serve we programs. have U.S. adoption EU will NPC this market the The help
successful Japan, on commercial Beyond in China for see the outside EU, U.S., and a the we U.S. geographies. our other arimoclomol also potential commercial of immediate the launch, focus
hypersomnia treatment. market for highlight highly for a possible The hypersomnia, idiopathic patients the designation patients review orphan Phase limited is FDA Now dosing underserved status been available and KPXXXX also potential and study as as options for as sleep by in rare compelling for with drug II has designated with which program an as segment. eligibility KPXXXX beginning this breakthrough clinical enrolling I the fast-track idiopathic will currently well our U.S. small a patient is in disorders, treatment
with Teva from dose is pricing Xywav, Jazz which believe ourselves, highest therefore, In KPXXXX us product a market share. the year treatment and economic per year a to Because is Pharmaceuticals' approximately the allows indication, capture is is approximately larger addition, is like significant between our strategy Pharmaceuticals' products aligned at the rare leads $XX,XXX highest intent arimoclomol the for a we treatment which that other differentiated per our and at commercialization in dose, capturing value. of that keep a portion PROVIGIL, which of to this options, this -- $XXX,XXX
end the the trial data II this data of year -- hypersomnia interim of the and Phase expect We by KPXXXX of top II idiopathic Phase from in third quarter line XXXX. by from
data be titration study because the Importantly, which the will phase, us to interim will is it meaningful also open-label in IH. start allow Phase an designing III
program additional in KPXXXX for are for program quarter The this We planning IND XXXX. filing expected during development of is also second narcolepsy. a the
LaDuane over will CFO, LaDuane? I that, call With turn our Clifton. the to
